Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh ( (AU:IMR) ) has provided an update.
Imricor Medical Systems, Inc. has announced a groundbreaking achievement by performing the world’s first Pulsed Field Ablation (PFA) under real-time MRI guidance in an iCMR lab. This advancement marks a significant milestone in Imricor’s PFA development program, demonstrating the flexibility and adaptability of their platform. The procedure, conducted using the second-generation Vision-MR Ablation Catheter, validates Imricor’s proprietary technology for integrating PFA energy with real-time MRI visualization. This innovation positions Imricor to meet the evolving needs of electrophysiologists globally and underscores the company’s commitment to advancing MRI-guided electrophysiology procedures.
The most recent analyst rating on (AU:IMR) stock is a Buy with a A$2.06 price target. To see the full list of analyst forecasts on Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:IMR Stock Forecast page.
More about Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh
Imricor Medical Systems, Inc. is a leader in developing MRI-compatible products for cardiac catheter ablation procedures. The company aims to enhance interventional medical procedures by enabling them to be performed under real-time MRI guidance, offering superior imaging capabilities compared to traditional x-ray fluoroscopy. Imricor’s primary product, the Vision-MR Ablation Catheter, is designed for real-time MRI-guided procedures and has been approved in several regions including the European Union, Saudi Arabia, and New Zealand. The company is working towards expanding its product approvals in the U.S. and other Middle Eastern countries.
Average Trading Volume: 268,578
Technical Sentiment Signal: Strong Buy
See more data about IMR stock on TipRanks’ Stock Analysis page.